Clinical Trials Logo
  1. Home
  2. Heart Failure, Congestive
  3. NCT00202579
  4. Details
NCT00202579 Clinical Trial

Efficacy and Safety of Ivabradine in Severe Congestive Heart Failure

Heart Failure, Congestive Clinical Trial

Official title:
Evaluation of the Effects on Peripheral and Central Haemodynamics Parameters, Safety, and Tolerance of Three-hour Intravenous Perfusion (0.1 mg/kg) of Ivabradine Given to Severe Congestive Heart Failure Patients

Clinical Trial Details — Status: Completed

Administrative data
NCT number NCT00202579
Other study ID # CL2-16257-053
Secondary ID
Status Completed
Phase Phase 2
First received September 12, 2005
Last updated March 13, 2018
Start date September 2004
Est. completion date February 2006

Study information
Verified date March 2018
Source Servier
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the effects on heart function of ivabradine administered to patients with severe chronic heart failure

Recruitment information / eligibility
Status Completed
Enrollment 12
Est. completion date February 2006
Est. primary completion date
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- systolic congestive heart failure

- sinus rhythm, HR >= 80bpm

Exclusion Criteria:

- unstable cardiovascular condition

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Ivabradine

Locations
Country Name City State
Italy Policlinico San Matteo Pavia

Sponsors (1)
Lead Sponsor Collaborator
Institut de Recherches Internationales Servier

Country where clinical trial is conducted

Italy, 

Outcome
Type Measure Description Time frame Safety issue
Primary Haemodynamic parameters
Primary Twelve-lead ECG
Primary Systolic and diastolic blood pressure
Secondary Echocardiography
Secondary Neurohormones
See also
  Status Clinical Trial Phase
Completed NCT01357850 - A Multi-center, Placebo-controlled Study to Evaluate the Safety of GSK716155 and Its Effects on Myocardial Metabolism, Myocardial Function, and Exercise Capacity in Patients With NYHA Class II/III Congestive Heart Failure Phase 2
Recruiting NCT00532688 - N-Acetylcysteine in Heart Failure With Coexistent Chronic Renal Failure Phase 2/Phase 3
Terminated NCT00383630 - Bone Marrow Cell Transplantation to Improve Heart Function in Individuals With End-Stage Heart Failure Phase 2
Completed NCT00531661 - CardioMEMS Heart Sensor Allows Monitoring of Pressure to Improve Outcomes in NYHA Class III Heart Failure Patients N/A
Completed NCT00241761 - Epidemiology of Depression and Heart Failure in Aging N/A
Completed NCT00159614 - Effect of KW-3902IV in Combination With IV Furosemide on Renal Function in Subjects With CHF and Renal Impairment Phase 2
Terminated NCT00125437 - Larger Dose of Spironolactone for the Treatment of Patients With Nonischemic Cardiomyopathy N/A
Completed NCT00149435 - Cardiovascular Health Study (CHS) Events Follow-up Study
Completed NCT00094263 - Long-Term Predictors of Morbidity in Older Age N/A
Terminated NCT00357591 - Randomized Trial for Patients With Chronic Heart Failure With Acute Decompensation N/A
Completed NCT00048425 - Evaluation of Intravenous Levosimendan Efficacy in the Short Term Treatment of Decompensated Chronic Heart Failure. Phase 3
Completed NCT00023556 - Genetic Architecture of Heart Disease in Rural Brazil N/A
Completed NCT00530426 - Heart Failure Registry Phase 4
Terminated NCT00190359 - Growth Hormone and Heart Failure N/A
Completed NCT00004562 - Occluded Artery Trial (OAT) Phase 3
Completed NCT00005265 - Natural History of Coronary Heart Disease N/A
Completed NCT02772068 - Hemodynamic Response to Exercise in HFpEF Patients After Upregulation of SERCA2a Early Phase 1
Completed NCT02925546 - A Phase I Study to Assess the Pharmacokinetics of GSK2798745 Tablets Phase 1
Completed NCT01074307 - A Prospective, Open-labeled, Multi-centric Trial in Subjects With Systolic Heart Failure to Evaluate Bisoprolol Treatment for the Effects on Surrogate Markers of Heart Failure in Korea Phase 4
Completed NCT00520806 - Efficacy and Safety of Relaxin for the Treatment of Acute Heart Failure Phase 2/Phase 3

External Links